Last reviewed · How we verify

NCT03613350

Prevalence Rates of USI, BO, DO and Their Clinical and Urodynamic Findings in Women With ≥Stage II Cystocele

Completed Last updated 3 August 2018
What this trial tests

trial testing Pad test in Lower Urinary Tract Symptom in Severe Cystocele Women in 480 participants. Completed in 31 May 2018.

Timeline
1 November 2011
Primary endpoint
31 January 2017
31 May 2018

Quick facts

Lead sponsorNational Taiwan University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment480
Start date1 November 2011
Primary completion31 January 2017
Estimated completion31 May 2018

Drugs / interventions tested

Conditions studied

Sponsor

National Taiwan University Hospital

Who can join

20 and older, female only, with Lower Urinary Tract Symptom in Severe Cystocele Women. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prevalence rates of urodynamic stress incontinence (USI), bladder oversensitivity (BO) /detrusor overactivity (DO) or both and their related clinical and urodynamic findings in women with ≥ pelvic organ prolapse quantification stage II cystocele are important for clinical consultation. Thus, the aim of this study was to elucidate the above findings and between-group associations.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Pad test

Trials testing the same drug.

Other National Taiwan University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03613350.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing